Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Tatsuya Oda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6115-0158; OpenAlex author ID A5044580459, A5090962497. Sources: OpenAlex.

Their work

Papers
28 (first author 14, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 28

  1. GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1002/advs.202514735↗
  2. Stromal FAP-targeted 18F-FAPI-74 PET/CT in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2026.07.004↗
  3. Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. Last author DOI 10.1038/s41416-026-03577-w↗
  4. Prognostic Value of Digitally Quantified CDX2 Expression in Pancreatic Ductal Adenocarcinoma Without Intestinal Differentiation. Co-author DOI 10.1177/10668969261437128↗
  5. Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-025-02404-1↗
  6. Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancer. Last author DOI 10.1186/s12957-025-03992-y↗
  7. Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. First author DOI 10.1155/2024/1529449↗
  8. Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. Last author DOI 10.3389/fcell.2024.1327772↗
  9. Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. First author DOI 10.1002/ijc.34362↗
  10. Total Superior Mesenteric Artery Nerve Plexus Preservation During Pancreaticoduodenectomy for Pancreatic Cancer. First author DOI 10.1007/s00268-023-07111-4↗
  11. rBC2LCN-reactive SERPINA3 is a glycobiomarker candidate for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/glycob/cwad009↗
  12. Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. First author DOI 10.1111/cas.15846↗
  13. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II… Last author DOI 10.1186/s12885-023-11110-y↗
  14. YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer. Co-author DOI 10.15252/embj.2022112614↗
  15. A Comparative Study of Patient-Derived Tumor Models of Pancreatic Ductal Adenocarcinoma Involving Orthotopic Implantation. Co-author DOI 10.1159/000521714↗
  16. Potential Metabolite Markers for Pancreatic Cancer Identified by Metabolomic Analysis of Induced Cancer-Associated Fibroblasts. Co-author DOI 10.3390/cancers14061375↗
  17. Quantitative structural analysis of glycans expressed within tumors derived from pancreatic cancer patient-derived xenograft mouse models. Co-author DOI 10.1016/j.bbrc.2020.11.087↗
  18. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic duc… First author DOI 10.1016/j.suronc.2021.101542↗
  19. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells. First author DOI 10.1111/cas.15023↗
  20. Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro. First author DOI 10.1002/2211-5463.12976↗
  21. Three-dimensional remnant pancreatic volume ratio indicates postoperative pancreatic exocrine insufficiency in pancreatic cancer patients after distal pancreat… Last author DOI 10.1016/j.pan.2020.06.018↗
  22. Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. First author DOI 10.1159/000513430↗
  23. A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate (LDC). First author DOI 10.1158/1535-7163.mct-17-0232↗
  24. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000000697↗
  25. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. First author DOI 10.1111/cas.12888↗
  26. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. First author DOI 10.1038/bjc.2014.49↗
  27. Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments. First author DOI 10.1097/mpa.0b013e318296f866↗
  28. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. First author DOI 10.1111/cas.12198↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Osamu Shimomura · 19 shared papers, 2016–2026 · strength 3.37
  2. Yoshihiro Miyazaki · 15 shared papers, 2020–2026 · strength 2.66
  3. Hiroaki Tateno · 10 shared papers, 2018–2026 · strength 1.77
  4. Yoshimasa Akashi · 13 shared papers, 2013–2026 · strength 1.65
  5. Hiromitsu Nakahashi · 7 shared papers, 2023–2026 · strength 1.47
  6. Yukihito Kuroda · 6 shared papers, 2020–2026 · strength 1.09
  7. Tomoaki Furuta · 6 shared papers, 2020–2026 · strength 1.00
  8. Tsuyoshi Enomoto · 9 shared papers, 2013–2025 · strength 0.85
  9. Koichiro Kumano · 3 shared papers, 2024–2026 · strength 0.72
  10. Masato Endo · 3 shared papers, 2023–2026 · strength 0.61
  11. Kiichiro Tsuchiya · 3 shared papers, 2023–2026 · strength 0.61
  12. Takahito Nakajima · 3 shared papers, 2023–2026 · strength 0.54
  13. Yusuke Ohara · 7 shared papers, 2013–2023 · strength 0.50
  14. Shuntaro Tsukamoto · 2 shared papers, 2025–2026 · strength 0.50
  15. Kentaro Hatano · 2 shared papers, 2023–2026 · strength 0.45
  16. Hideyuki Sakurai · 3 shared papers, 2021–2025 · strength 0.43
  17. Haruko Numajiri · 3 shared papers, 2021–2025 · strength 0.43
  18. Ryoichi Miyamoto · 6 shared papers, 2013–2020 · strength 0.39
  19. Yasuyuki S. Kida · 2 shared papers, 2020–2022 · strength 0.36
  20. Sota Kimura · 3 shared papers, 2018–2021 · strength 0.30
  21. Yuichi Hiroshima · 2 shared papers, 2021–2025 · strength 0.30
  22. Dinh Xuan Tuan Anh · 1 shared paper, 2026 · strength 0.30
  23. Nobuhiro Ohkohchi · 5 shared papers, 2013–2018 · strength 0.27
  24. Kazuya Yamagata · 1 shared paper, 2023 · strength 0.19
  25. Shuuji Mawaribuchi · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.